Rapport Therapeutics, Inc.

RAPP

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0002012593


None

No letter

5 of 14 inputs computable; 7 are required, with a score in every sleeve


Scoreboard	
Reliability	0.87 AUC filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025
Peer failure rate	1.03% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$120M to $591M assets total assets $512.4M
Warnings	dilution, thin data not computable: degenerate inputs, fortress balance sheet
Inputs computable	5 of 14
Graded from	filings received through Mar 10, 2026 240 days before the rescan; latest periodic filing 10-Q received Nov 4, 2026
Last close	$25.91 2026-11-04; market equity $1.5B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 10, 2026

We are a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders. Our foundational science has elucidated the complexities of neuronal receptor biology and enables us to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor associated proteins ("RAPs"), the latter of which play crucial roles in regulating receptor expression and function.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 58.6						
Gross profitability	not computable	32.4%				
one or more required annual facts are missing						
Return on invested capital	not computable	9.3%				

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

one or more required annual facts are missing					
Accruals ratio	(5.8%)	(6.6%)	58.6	801	2025-12-31
Gross margin stability, five years	not computable	2.8 pts			
five annual gross margins are required; found 0					
Solvency, sleeve percentile 18.2					
Twelve-month failure probability	0.09%	0.08%	50.0	249	2026-09-30
Altman Z double-prime	21.32	(0.35)	2.4	746	2025-12-31
Net debt to EBITDA	not computable	1.82x			
one or more required annual facts are missing					
Interest coverage	not computable	(4.51x)			
one or more required annual facts are missing					
Current ratio	26.17x	2.92x	2.3	827	2025-12-31
Growth and financing, sleeve percentile 67.9					
Revenue growth, three-year compound	not computable	10.1%			
four annual observations are required; found 0					
Free cash flow growth, three-year compound	not computable	10.9%			
four consecutive annual FCF observations are required; found 2					
Reinvestment rate	not computable	37.1%			
a prior annual working-capital observation is required					
Asset growth, three years	not computable	2.2%			
four annual observations are required; found 2					
Net share issuance, one year	31.0%	2.5%	67.9	630	2026-03-02

Warnings

2 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 31.0%
Thin data	5 of 14 grade factors are computable; minimum is 7

What the price implies

at the 2026-11-04 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	16.1%	(2.2%)	59
Distance from 52-week high	(50.6%)	(26.8%)	27
EBIT to enterprise value	not computable	(1.4%)	
Free cash flow yield	(5.7%)	(0.9%)	39
Book value to price	0.25	0.27	48
Sales to price	not computable	0.28	
Composite equity issuance, five years	not computable	20.5%	
Relative strength against the sector, log excess return	(0.02)	(0.19)	59

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$74.8M
Operating cash flow, four quarters	-$120.8M
Months of runway	7.4
Days since last periodic filing	1 (10-Q received Nov 4, 2026)
Median daily dollar volume, 63 sessions	$14.5M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$111.5M	2025-12-31	2026-03-10	10-K	26-099360
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$87.5M	2025-12-31	2026-03-10	10-K	26-099360
3	assets	us-gaap:Assets	$512.4M	2025-12-31	2026-03-10	10-K	26-099360
4	assets	us-gaap:Assets	$314.9M	2024-12-31	2026-03-10	10-K	26-099360
5	current assets	us-gaap:AssetsCurrent	$498.6M	2025-12-31	2026-03-10	10-K	26-099360
6	current liabilities	us-gaap:LiabilitiesCurrent	$19.0M	2025-12-31	2026-03-10	10-K	26-099360
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$235.2M	2025-12-31	2026-03-10	10-K	26-099360
8	operating income	us-gaap:OperatingIncomeLoss	-$125.1M	2025-12-31	2026-03-10	10-K	26-099360
9	book equity	us-gaap:StockholdersEquity	$484.7M	2025-12-31	2026-03-10	10-K	26-099360
10	liabilities	us-gaap:Liabilities	$27.8M	2025-12-31	2026-03-10	10-K	26-099360
11	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$2.4M	2024-12-31	2026-03-10	10-K	26-099360
12	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$839,000	2024-12-31	2026-03-10	10-K	26-099360
13	operating income	us-gaap:OperatingIncomeLoss	-$83.1M	2024-12-31	2026-03-10	10-K	26-099360
14	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$78.3M	2024-12-31	2025-03-11	10-K	25-036828
15	income tax	us-gaap:IncomeTaxExpenseBenefit	$0	2024-12-31	2026-03-10	10-K	26-099360
16	current assets	us-gaap:AssetsCurrent	$309.8M	2024-12-31	2026-03-10	10-K	26-099360
17	current liabilities	us-gaap:LiabilitiesCurrent	$8.8M	2024-12-31	2026-03-10	10-K	26-099360
18	shares outstanding	dei:EntityCommonStockSharesOutstanding	47,792,943	2026-03-02	2026-03-10	10-K	26-099360
19	shares outstanding	dei:EntityCommonStockSharesOutstanding	36,496,437	2025-03-01	2025-03-11	10-K	25-036828

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.